- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04322136
AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion (AMPLE-3)
The Australasian Malignant PLeural Effusion (AMPLE) Trial - 3: A Randomised Study of the Relative Benefits of Combined Indwelling Pleural Catheter (IPC) and Talc Pleurodesis Therapy or Video-Assisted Thoracoscopic Surgery (VATS) in the Management of Patients With Malignant Pleural Effusion.
The purpose of this study is to determine if an indwelling catheter is more effective than surgical pleurodosis in treating malignant pleural effusion.
Who is it for?
You may be eligible for this study if you are an adult who is suffering from symptomatic proven pleural malignancy or an otherwise unexplained pleural effusion.
Study details
Consenting participants will be randomised to one of two treatment arms:
- Arm 1: Indwelling pleural catheter. A long term catheter is inserted under the skin in order to allow ongoing drainage of the pleural fluid. Participants will then be instructed to undergo a daily drainage regimen for 14 days at home.
- Arm 2: Surgical pleurodesis. Participants under a key-hole surgery to remove fluid and facilitate lung re-expansion.
Participants will then be followed up at discharge, 14 days, monthly for 6 months and then every 3 months up to one year post-procedure. These visits will include completion of Quality of Life questionnaires, a chest xray, an ultrasound (if thought necessary) and if you are at the lead site (Sir Charles Gairdner Hospital) a review of your Actigraphy logs up to 6 months after discharge.
It is hoped this research will help to provide effective symptom control with minimal intervention for those with malignant pleural effusion.
Study Overview
Status
Conditions
Detailed Description
Participants will be randomly assigned (1:1) to one of two arms:
Arm 1: Indwelling pleural catheter (with talc pleurodesis if suitable) Arm 2: Pleurodesis via Video-assisted thoracoscopic surgery
Arm 1: Indwelling pleural catheter is a long-term catheter that is tunnelled under the skin and allows ongoing drainage of pleural fluid by the patient or carer at home. It is inserted using local anaesthetic with or without sedation depending on local practice. An experienced respiratory physician inserts the catheter. Once the catheter is inserted, the pleural fluid will be evacuated as completely as possible. If the lung fully re-expands and there is no contraindication to talc pleurodesis, 4-5g of sterile graded talc will be instilled via the IPC. The participant will then be discharged on a daily drainage regimen for 14 days. The drainage will either be performed by the participant's carer or nurses in the community. A bottle or bag will be attached to the drain to allow for removal of accumulated pleural fluid. Once completed the drain will be reattached to the pleural catheter. At review in clinic on day 14 (+/- 2 days), the participant will be assessed for spontaneous pleurodesis (<50ml drainage on 3 consecutive drainage attempts). If pleurodesis has occurred and there is no residual symptomatic effusion, arrangements will be made for IPC removal. Otherwise the participant will switch to a symptom-guided drainage regimen. If the lung does not fully re-expand following complete fluid evacuation, they will be discharged on a symptom-guided regimen without instillation of talc. The drainage regimen will continue for the duration of the study and beyond if pleurodesis has not occurred and pleural fluid continues to accumulate. All participants will remain under the care of their study doctors who are also their usual physicians, after the end of the study.
Arm 2: Video-assisted thoracoscopic surgery is a type of key-hole surgery performed under general anaesthetic and usually single lung ventilation by a cardio-thoracic surgeon. This is expected to take about 1 hour. Between one and three ports are used to insert a camera and instruments into the chest cavity. Adhesions can be broken down if present and the lining of the lung (visceral pleura) can sometimes be removed (decortication) to facilitate lung re-expansion. The surgeon can then perform either mechanical abrasion or talc poudrage to induce inflammation and subsequent pleurodesis. A chest drain is left in situ post-operatively and is removed when the fluid draining is below a certain volume depending on local practice.
Participants in both arms will be reviewed at the same time points - at discharge, 14 days post-procedure, monthly to 6 months, then 3-monthly to 1 year. The reviews will include quality of life and breathlessness questionnaires.
All data will be obtained by the designated study research team who will carry out the IPC insertions and where VATs pleurodesis is undertaken, the research team will liaise directly with the study surgeon.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: YC Gary Lee, MBChB PhD
- Phone Number: +61861510913
- Email: gary.lee@uwa.edu.au
Study Contact Backup
- Name: Calvinjit Sidhu, MBBS
- Phone Number: +61437672808
- Email: calvinjit.sidhu@health.wa.gov.au
Study Locations
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Recruiting
- Institute for Respiratory Health
-
Contact:
- YC Gary Lee, MBChB PhD
- Phone Number: +61861510913
- Email: gary.lee@uwa.edu.au
-
Contact:
- Calvinjit Sidhu, MBBS
- Phone Number: +61437672808
- Email: calvinjit.sidhu@health.wa.gov.au
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with a symptomatic MPE*
- Predicted survival of more than 6 months
Eastern Cooperative Oncology Group (ECOG) score = Peformance status defined as a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc. ECOG 0-1 (or ECOG greater than or equal to 2 if it is felt that removal of pleural fluid would improve their status to 0 or 1).
- MPE is defined as histologically/cytologically proven pleural malignancy or an otherwise unexplained pleural effusion in the context of clinically proven cancer elsewhere.
Exclusion Criteria:
- Age <18yrs;
- Unfit to undergo a surgical procedure (American Society of Anaesthesiologists Score >/=4); 3. Pleural infection;
4. Chylothorax; 5. Pregnancy or lactation; 6. Uncorrectable bleeding diathesis; 7. Previous ipsilateral lobectomy/pneumonectomy; 8. Inability to consent or comply with protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: IPC (with talc pleurodesis if suitable)
The patients will undertake daily drainage to day 14 post insertion. The drainage will either be performed by the participant's carer or nurses in the community. A bottle or bag will be attached to the drain to allow for removal of accumulated pleural fluid. Once completed the drain will be reattached to the pleural catheter. Participants will be taught how to perform pleural drainage by the main study doctor at the hospital or a specialist nurse. They will drain their own IPCs at home with the either the help of a family member or friend or have access to community nursing support systems. |
Once the indwelling pleural catheter is inserted, the pleural fluid will be evacuated as completely as possible.
If the lung fully re-expands, 4-5g of sterile graded talc will be instilled via the IPC.
The participant will then be discharged on a daily drainage regimen for 14 days.
At review in clinic on day 14, the participant will be assessed for spontaneous pleurodesis (<50ml drainage on 3 consecutive drainage attempts).
If pleurodesis has occurred and there is no residual symptomatic effusion, arrangements will be made for IPC removal.
Otherwise the participant will switch to a symptom-guided drainage regimen.
If the lung does not fully re-expand following complete fluid evacuation, they will be discharged on a symptom-guided regimen without instillation of talc.
The drainage regimen will continue for the duration of the study and beyond if pleurodesis has not occurred and pleural fluid continues to accumulate.
|
Other: Pleurodesis via VATS
Participants will undergo VATS within two weeks of randomisation.
VATS is usually performed in an operating theatre, using either general anaesthesia or local anaesthesia with sedation.
The pleural fluid will be removed and adhesions can be divided (adhesiolysis).
Assessment of lung re-expansion will be performed intra-operatively.
If lung re-expansion is adequate (as judged by the operating surgeon), a variety of techniques may be employed to induce a pleurodesis, including, but not limited to, talc poudrage and mechanical abrasion.
Decortication may be performed if deemed appropriate and feasible by the operating surgeon.
A chest drain will be left in situ after the surgery.
Post-operative care will be administered as per local practice.
|
Video-assisted thoracoscopic surgery is a type of key-hole surgery performed under general anaesthetic and usually single lung ventilation by a cardio-thoracic surgeon.
This is expected to take about 1 hour.
Between one and three ports are used to insert a camera and instruments into the chest cavity.
Adhesions can be broken down if present and the lining of the lung (visceral pleura) can sometimes be removed (decortication) to facilitate lung re-expansion.
The surgeon can then perform either mechanical abrasion or talc poudrage to induce inflammation and subsequent pleurodesis.
A chest drain is left in situ post-operatively and is removed when the fluid draining is below a certain volume depending on local practice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Need for an ipsilateral pleural intervention
Time Frame: Participants will be followed for a maximum of 12 months or until death if sooner.
|
Proportion of participants requiring an ipsilateral (on the same side) pleural procedure for management of symptomatic re-accumulation of pleural fluid including surgical procedure, chest drain insertion, attempted therapeutic thoracentesis. This is a composite outcome. Data will be obtained from the participants and the hospital record. |
Participants will be followed for a maximum of 12 months or until death if sooner.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Need for repeat ipsilateral pleural intervention including diagnostic aspiration
Time Frame: The study is for 12 months or until death if prior.
|
Proportion of participants requiring an ipsilateral pleural procedure including diagnostic aspirate. Data will be obtained from the participants and the hospital record. |
The study is for 12 months or until death if prior.
|
Time to symptomatic effusion recurrence
Time Frame: The study is for 12 months or until death if prior.
|
Time to effusion recurrence - will be assessed using chest x-ray and ultrasound at each visit.
Recurrent effusion is defined as greater than 25% opacity on chest x-ray on the side of the intervention as judged by two independent clinicians and evidence of pleural fluid on ultrasound.
|
The study is for 12 months or until death if prior.
|
All-cause hospital days
Time Frame: The study is for 12 months or until death if prior.
|
Length of stay post-procedure and hospitalization for any cause (except for elective admissions for chemotherapy) will be recorded for all patients post randomisation. Admissions will be analysed as total admission days and also pleural-related admission days. The data will be collected from participants and the hospital records. |
The study is for 12 months or until death if prior.
|
Degree of breathlessness
Time Frame: Scores will be recorded daily for 28 days, then monthly to 6 months and 3-monthly until 12 months.
|
Degree of breathlessness will be measured by a 100mm Visual Analogue Scale (VAS).
The VAS is a 100mm line anchored with "no breathlessness" at 0mm and "worst breathlessness imaginable" at 100mm.
|
Scores will be recorded daily for 28 days, then monthly to 6 months and 3-monthly until 12 months.
|
Pain scale
Time Frame: Scores will be recorded daily for 28 days, monthly to 6 months and then 3-monthly to 12 months
|
Pain will be assessed using a 100mm visual analogue scale.
The 100mm horizontal line will be anchored with "no pain" at 0mm and "worst pain imaginable" at 100mm.
|
Scores will be recorded daily for 28 days, monthly to 6 months and then 3-monthly to 12 months
|
Quality of Life (QoL)
Time Frame: QoL will be measured at baseline, day 7-10 post-procedure, then monthly to 6 months then 3 monthly to 12 months.
|
Quality of Life (QoL) will be measured using two instruments: EQ-5D-5L is a standardised measure of HRQoL that comprises five dimensions including mobility, self-care, usual activities, pain//discomfort and anxiety/depression.
VAS QoL records self-rated health on a 100mm line anchored with "best imaginable health state" at 0mm and "worst imaginable health state" at 100mm.
|
QoL will be measured at baseline, day 7-10 post-procedure, then monthly to 6 months then 3 monthly to 12 months.
|
Physical activity patterns
Time Frame: Monthly to 12 months at lead site only.
|
Actigraphy is one part of the study and is an outcome comprising a few different factors.
Physical activity patterns, vigorous activity and periods of sedentary behaviour, will be evaluated by a well validated triaxial accelerometer (ActiGraph GT3X+, Pensacola, FL, USA).
Objective physical activity patterns will be assessed by 7-day triaxial accelerometer assessment providing an indication of functional status.
The Actigraph device is reliable, with excellent test-retest reproducibility in cancer research and rated as 'user friendly' by both healthy and patient populations.
|
Monthly to 12 months at lead site only.
|
Adverse events from time of enrolment
Time Frame: Assessed continuously up to 12 months.
|
Adverse events from randomization until end of follow-up or death.
An adverse event is defined as any participant-reported or medical records complications associated with the IPC or VATS pleurodesis, such as pleural infection, cellulitis, pain, symptomatic loculation, tube blockage, catheter tract metastases, parenchymal air leak etc., and any peri/post-procedural complications such as prolonged air-leak, atelectasis, pneumonia, cardiovascular complications, acute kidney injury or drop in haemoglobin requiring transfusion.
|
Assessed continuously up to 12 months.
|
Overall survival from randomisation.
Time Frame: From randomisation up to 12 months
|
Overall Survival will be recorded from date of enrolment to death or end of study follow-up.
Survival difference between IPC and VATS management of malignant pleural effusion has not been previously studied.
|
From randomisation up to 12 months
|
Pleural-related hospital days.
Time Frame: The study is for 12 months or until death if prior.
|
Pleural-related hospital days. Length of stay post-procedure and hospitalization for any cause (except for elective admissions for chemotherapy) will be recorded for all patients post randomisation. Admissions will be analysed as total admission days and also pleural-related admission days. The data will be collected from participants and the hospital records. |
The study is for 12 months or until death if prior.
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMPLE-3
- ACTRN12618001013257 (Other Identifier: ANZCTR)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Indwelling pleural catheter (with talc pleurodesis if suitable)
-
National University Hospital, SingaporeUnknownPleural Effusion, MalignantSingapore
-
Guy's and St Thomas' NHS Foundation TrustBecton, Dickinson and CompanyUnknownPleural Effusion, MalignantUnited Kingdom
-
Heidelberg UniversityCompleted
-
University of OxfordTerminatedPleural EffusionUnited Kingdom
-
Rambam Health Care CampusUnknownLung Neoplasms | Pleural Effusion, Malignant
-
The Cooper Health SystemUnknownPleural Diseases | Pleural Effusion | Malignant Pleural EffusionUnited States